Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mode of action

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    99 result(s) found for: Mode of action. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2014-004776-27 Sponsor Protocol Number: MK-0476-388 Start Date*: 2015-04-03
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase Ib Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Bronchodilatory Effect of MK-0476 in Patients with Chronic Asthma
    Medical condition: Chronic asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-000581-58 Sponsor Protocol Number: BioBioV4.0 Start Date*: 2015-10-14
    Sponsor Name:Revmatologicky ustav Praha
    Full Title: A Randomized, Biomarker Trial to Predict Therapeutic Responses of Patients with Rheumatoid Arthritis to a Specific Biologic Mode of Action
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000139-21 Sponsor Protocol Number: BIOBIO-Study Start Date*: 2012-05-14
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Innere Medizin III
    Full Title: A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients with Rheumatoid Arthritis to a Specific Biologic Mode of Action
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021879-85 Sponsor Protocol Number: 10050 Start Date*: 2010-09-08
    Sponsor Name:University of Nottingham
    Full Title: Mode of action of Moviprep:impact on distribution of intestinal fluid and colonic microbiota
    Medical condition: for bowel cleansing prior to any clinical procedure requiring a clean bowel, e.g, bowel endoscopy, lower gastrointestinal tract radiology or digestive tract surgery.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004961-14 Sponsor Protocol Number: UV2013/4 Start Date*: 2014-06-11
    Sponsor Name:Kliniken Kärnan Urology Centre
    Full Title: Pilot study to investigate the mode of action (MoA) of Uro-Vaxom® on a molecular level in pre-menopausal women suffering from recurrent urinary tract infections (rUTI)
    Medical condition: Recurrent urinary tract infections (rUTI)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10038140 Recurrent urinary tract infection LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000859-27 Sponsor Protocol Number: HS_Apremilast Start Date*: 2017-01-23
    Sponsor Name:Erasmus University Medical Center
    Full Title: Efficacy and mode of action of apremilast (Otezla) in moderate hidradenitis suppurativa. An exploratory pilot study.
    Medical condition: Hidradenitis suppurativa, acne inversa, ectopic acne
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004798-17 Sponsor Protocol Number: CAIN457F2301T Start Date*: 2015-05-26
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Evaluation of inflammatory and structural joint damage in patients with psoriasis and psoriatic arthritis treated with secukinumab: A phase 2, single arm, single centre mode of action study (Psoria...
    Medical condition: Psoriasis or prosiatric arthritis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037154 Psoriasis aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002978-52 Sponsor Protocol Number: CNTO1959HDS2002 Start Date*: 2019-07-16
    Sponsor Name:Universitair Medisch Centrum Groningen
    Full Title: Guselkumab for hidradenitis suppurativa, a mode of action study.
    Medical condition: Hidradenitis suppurativa
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003617-33 Sponsor Protocol Number: 03-2005 Start Date*: Information not available in EudraCT
    Sponsor Name:Charité
    Full Title: A Randomised Cross-Over Study to Explore the Pathophysiological Mechanisms Involved in the Treatment of Actinic Keratoses with Solaraze
    Medical condition: actinic keratosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003327-36 Sponsor Protocol Number: ART1 Start Date*: 2007-01-08
    Sponsor Name:Guy's & St Thomas' NHS Foundation Trust [...]
    1. Guy's & St Thomas' NHS Foundation Trust
    2. King's College London
    Full Title: Evaluation of the efficacy of colchicine with and without betamethasone mouthwash in the management of recurrent aphthous stomatitis
    Medical condition: Recurrent aphthous stomatitis (RAS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013398-16 Sponsor Protocol Number: HULP-Nefro001 Start Date*: 2009-11-16
    Sponsor Name:Rafael Selgas
    Full Title: ACONDICIONAMIENTO DEL DONANTE CADÁVER MEDIANTE LA ADMINISTRACIÓN DE TIMOGLOBULINA PARA DISMINUIR EL ESTADO PRO-INFLAMATORIO TRAS LA MUERTE CEREBRAL
    Medical condition: Eficacia: Demostrar que la administración de timoglobulina en el donante cadáver reduce la expresividad antigénica del injerto, mediante una disminución de la expresión de marcadores de inflamación...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000253-30 Sponsor Protocol Number: LP0075-34 Start Date*: 2012-11-08
    Sponsor Name:LEO Pharma A/S
    Full Title: An exploratory study evaluating the efficacy of cromoglicate cream compared to cream vehicle in the treatment of itch in psoriasis
    Medical condition: itchy psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004300-65 Sponsor Protocol Number: AGO/2016/012 Start Date*: 2017-09-26
    Sponsor Name:Ghent University Hospital
    Full Title: Optimizing the Biologic Treatment Strategy in Rheumatoid Arthritis (RA) Patients that have failed a Tumor Necrosis Factor-alpha (TNFα) blocking Agent by immunoscintigraphy with Technetium-labeled C...
    Medical condition: rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004748-62 Sponsor Protocol Number: 05PF2005 Start Date*: 2021-12-17
    Sponsor Name:Q-Med AB, part of the Galderma Group
    Full Title: A Phase IV, Randomized, Interventional, Study to Assess Subject Treatment Session Perception and Investigator Treatment Experience of Alluzience and Vacuum-Dried Botulinum Neurotoxin Type A for ...
    Medical condition: Moderate to severe glabellar lines (GL).
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-005063-13 Sponsor Protocol Number: Repha_1410 Start Date*: 2017-05-08
    Sponsor Name:Repha GmbH
    Full Title: Investigation of Efficacy, Safety, Acid Resistance and Mode of Action of Lipases in Nortase and Kreon with the Pancreo-Lip 13C breath test in Subjects with Severe Exocrine Pancreatic Insufficiency
    Medical condition: Severe exocrine pancreatic insufficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10033628 Pancreatic insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002708-28 Sponsor Protocol Number: REDIV/002/17 Start Date*: 2018-02-23
    Sponsor Name:Alfasigma S.p.a
    Full Title: Rifaximin delayed release (400 mg tablet) for the prevention of recurrent acute diverticulitis and diverticular complications. A phase II, multicenter, double-blind, placebo-controlled, randomized ...
    Medical condition: Prevention of recurrent acute diverticulitis and diverticular complications
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10052812 Acute diverticulitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) HU (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) PT (Completed) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2008-000121-19 Sponsor Protocol Number: CapRI 2 Start Date*: 2008-08-11
    Sponsor Name:University of Heidelberg
    Full Title: A Randomized Multicentre Phase II Trial Comparing Adjuvant Therapy in Patients with Resected Pancreatic Adenocarcinoma Treated with Interferon Alpha-2b and 5-FU Alone or in Combination with Either ...
    Medical condition: Patients with Resected Pancreatic Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033608 Pancreatic cancer resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018340-14 Sponsor Protocol Number: 10085 Start Date*: 2010-11-25
    Sponsor Name:University of Nottingham
    Full Title: Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D).
    Medical condition: Diarrhoea-predominant irritable bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003418-42 Sponsor Protocol Number: WOE_2013_TUE Start Date*: 2015-03-23
    Sponsor Name:Wörwag Pharma GmbH & Co. KG
    Full Title: Effect of Mg-Orotate administration on cardiocirculatory Performance, the muscular concentration of phosphocreatine and the adaptation of muscle cellular level: A double blind, randomized, placebo-...
    Medical condition: Evaluation of cardiocirculatory performance using clinical and relevant muscle laboratory parameters while taking Mg-Orotate and application of workouts
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004088-34 Sponsor Protocol Number: APHP180571 Start Date*: 2020-02-04
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP)
    Full Title: Effect of two injections of synchronized methotrexate with the first injection of Adalimumab to prevent anti-adalimumab immunization in spondyloarthritis
    Medical condition: adult patients with Axial Spondyloarthritis who have an indication for anti-TNF therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10028395 Musculoskeletal and connective tissue disorders SOC
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10071400 Axial spondyloarthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 19:23:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA